ArticleNature communications2013
SUMO2/3 modification of cyclin E contributes to the control of replication origin firing.
Article in Nature communications, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 22 citations in OpenAlex.
- Targeting SUMOylation in glioblastoma: A novel avenue for therapy and biomarker discovery.Genes & diseases · 2026Review
- Sumoylation of cyclin and its therapeutic potential for cancer.Animal cells and systems · 2026Review
- Review
- DeSUMOylation of Apoptosis Inhibitor 5 bymBio · 2021Article
- Revised annotation and extended characterizations of components of thePlant direct · 2020Article
- Multisite SUMOylation restrains DNA polymerase η interactions with DNA damage sites.The Journal of biological chemistry · 2020Article
- SUMO Protease SMT7 Modulates Ribosomal Protein L30 and Regulates Cell-Size Checkpoint Function.The Plant cell · 2020Article
- The requirement of SUMO2/3 for SENP2 mediated extraembryonic and embryonic development.Developmental dynamics : an official publication of the American Association of Anatomists · 2020Article
- SUMO1 Modification Facilitates Avibirnavirus Replication by Stabilizing Polymerase VP1.Journal of virology · 2019Article
- SUMOylation in Glioblastoma: A Novel Therapeutic Target.International journal of molecular sciences · 2019Review
- UBA2 promotes proliferation of colorectal cancer.Molecular medicine reports · 2018Article
- Article
- Roles of SUMO in Replication Initiation, Progression, and Termination.Advances in experimental medicine and biology · 2017Review
- Functions of Ubiquitin and SUMO in DNA Replication and Replication Stress.Frontiers in genetics · 2016Review
- SUMOylation-Mediated Regulation of Cell Cycle Progression and Cancer.Trends in biochemical sciences · 2015Review
- Identification of small ubiquitin-like modifier substrates with diverse functions using the Xenopus egg extract system.Molecular & cellular proteomics : MCP · 2014Article
- SUMO1 modification stabilizes CDK6 protein and drives the cell cycle and glioblastoma progression.Nature communications · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The small ubiquitin-like modifier (SUMO) pathway is essential for the maintenance of genome stability. We investigated its possible involvement in the control of DNA replication during S phase by using the Xenopus cell-free system. Here we show that the SUMO pathway is critical to limit the number and, thus, the density of replication origins that are activated in early S phase. We identified cyclin E, which regulates cyclin-dependent kinase 2 (Cdk2) to trigger origin firing, as an S-phase substrate of this pathway. We show that cyclin E is dynamically and highly conjugated to SUMO2/3 on chromatin, independently of Cdk2 activity and origin activation. Moreover, cyclin E is the predominant SUMO2/3 target on chromatin in early S phase, as cyclin E depletion abolishes, while its readdition restores, the SUMO2/3 signal. Together, our data indicate that cyclin E SUMOylation is important for controlling origin firing once the cyclin E-Cdk2 complex is recruited onto replication origins.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.